Publication
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMelanomacivic_curation1.00
- drugBRAF Inhibitorcivic_curation1.00
- drugMitogen-Activated Protein Kinase Kinase Inhibitorcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF A598Vcivic_curation1.00
- variantBRAF G469civic_curation1.00
- variantBRAF V600Dcivic_curation1.00
- variantBRAF V600_K601>Ecivic_curation1.00
Curated evidence
Evidence citing this paper (21)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31580757
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF A598V1 | ||||||||
| BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Melanoma | Predictive | C | Does Not Support Sensitivity Response | 3 | accepted | EID7635In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF G4692 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID7623In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID7634In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF G593D1 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID7624In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF K601E1 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | B | Does Not Support Sensitivity Response | 4 | submitted | EID7622In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF L5973 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | B | Does Not Support Sensitivity Response | 4 | submitted | EID7621In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| 〃 | Melanoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7626In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7632In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF T599_V600insT1 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID7625In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF V600D2 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7616In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Melanoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7629In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF V600G1 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID7618In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF V600_K601>E2 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID7617In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Melanoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7630In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF V600L1 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID7619In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF V600M1 | ||||||||
| BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7631In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF V600R2 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7615In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7628In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF V600_S602>DT1 | ||||||||
| BRAF Inhibitor | Melanoma | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID7620In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| BRAF V601E2 | ||||||||
| BRAF Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7633In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | Melanoma | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID7627In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated wi… (full text at CIViC) PMID 31580757 · Menzer et al., 2019 · Open in CIViC | civic |